IPKat: Further analysis of Generics (t/a Mylan) v Yeda and Teva

No items found.
​
July 18, 2012
#
Litigation
#
Life
Table of contents
  • Toc Heading
  • Toc Heading

In addition to an earlier summary by Darren Smyth of the ruling in Generics (t/a Mylan) v Yeda and Teva, Darren has provided further analysis for the IPKat.

Darren's article looks at the issue of the interpretation and clarity of two features in the patent claims.

The case relates to a European patent owned by Yeda (for which Teva is exclusive licensee) for Teva’s glatiramer acetate product marketed under the trademark Copaxone.

Related articles

See all articles

Design right re-design – an opportunity for UK business to shape design protection to suit its needs
22 August 2012
The UK Intellectual Property Office (UK IPO) has recently published a consultation document on the proposed reform of the UK Designs Legal Framework.
​
Budejovicky Budvar Narodni Podnik v Anheuser -Busch Inc [2012] EWCA Civ 880 (03 July 2012)
01 August 2012
The Court of Appeal recently allowed an appeal by Budejovicky Budvar Narodni Podnik (BB), against a decision that found its “Budweiser” mark invalid following an attack by Anheuser-Busch (AB) which...
​
Patentability of computer programs - High Court judgment gives rise to useful examples of a “technical effect”
31 July 2012
(HTC Europe Co Ltd v Apple Inc [2012] EWHC 1789).A further decision in the so-called “smartphone wars” was issued by the High Court recently in relation to a patent dispute between HTC Europe Co Ltd...
​